Reducing addiction, promoting competition FDA priorities for 2018
The Food and Drug Administration today announced four priority areas for additional policy activity in 2018: reducing addiction to opioid drugs and cigarettes; promoting innovation and competition; empowering consumers to make informed decisions; and strengthening the FDA workforce. Specific policy efforts include new steps to support and streamline development and approval of treatments that address addiction; reducing burdens for creating and approving generic drugs; and extending new hiring and pay authorities to recruit and retain FDA staff.
Related News Articles
Blog
Even before the COVID pandemic, the mental health and wellness of our young people was failing. The pandemic exacerbated the crisis and made it difficult for…
Headline
A new AHA video highlights how Corewell Health is transforming youth behavioral health care access in rural Michigan through school-based clinics and…
Headline
The Departments of Labor, Health and Human Services, and the Treasury May 15 announced that they will not enforce the 2024 mental health parity final rule, a…
Headline
Overdose deaths in the U.S. fell 26.9% last year to 80,391, according to estimates from the Centers for Disease Control and Prevention. The agency reported…
Headline
Beth Heinz, senior vice president, Women’s and Children’s Services at Yale New Haven Health, and Cheri Johnson, chief nursing officer, Woman’s Hospital in…
Headline
Zaira Khalid, M.D., senior staff geriatric psychiatrist at Henry Ford Behavioral Health Hospital, discusses the unique physical, emotional and social needs of…